E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials
John M. Galla,Kenneth W. Mahaffey,Shelly Sapp,John H. Alexander,Matthew T. Roe,E. Magnus Ohman,Christopher B. Granger,Paul W. Armstrong,Robert A. Harrington,Harvey D. White,Maarten L. Simoons,L. Kristin Newby,Robert M. Califf,Eric J. Topol +13 more
TL;DR: CK-MB remains a reliable marker for myocardial necrosis and a strong predictor of worse prognosis and all patients with ACS should have CK-MB measurement to search for cardiac ischemia.
Journal ArticleDOI
Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events
TL;DR: The adverse impact of MS or DM was greater among men, and the presence of both conditions increases the risk substantially for cardiovascular events among women.
Journal ArticleDOI
The REPLACE 1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade
A. Michael Lincoff,John A. Bittl,Neal S. Kleiman,Dean J. Kereiakes,Robert A. Harrington,Ian J. Sarembock,J. Daniel Jackman,Sameer Mehta,Elizabeth F. Maierson,Derek P. Chew,Eric J. Topol +10 more
Journal ArticleDOI
Cystic fibrosis in an era of genomically guided therapy
TL;DR: The genomic pathophysiology of CF is explored and how therapies such as ivacaftor provide benefit to those with the disease but at a considerably elevated price point is explored.
Journal ArticleDOI
The benefit of abciximab in percutaneous coronary revascularization is not device-specific
Deepak L. Bhatt,A. Michael Lincoff,Robert M. Califf,Maarten L. Simoons,James E. Tcheng,Sorin J. Brener,Katherine E. Wolski,Eric J. Topol +7 more
TL;DR: Findings from all the controlled coronary revascularization trials using abciximab demonstrate that a decrease in death and MI is achieved with abcximab regardless of the type of device used, without an increase in significant bleeding complications.